SGIOF - Shionogi to deliver additional 1M courses of COVID pills to Japan

• Japanese drugmaker Shionogi ( OTCPK:SGIOF ) ( OTCPK:SGIOY ) announced Tuesday that the company won a contract from the government of Japan to supply additional 1M courses of its oral COVID-19 antiviral Xocova.

• Xocova, a collaboration between Shionogi ( OTCPK:SGIOF ) and Hokkaido University, is a protease inhibitor authorized in Japan under the emergency regulatory approval system for COVID-19.
• The contract is an extension of the initial agreement signed between the Ministry of Health, Labour, and Welfare in Japan and Shionogi ( OTCPK:SGIOF ) in March 2022 to deliver 1M courses of Xocova immediately after approval.
• The company intends to deliver the additional doses by the year-end. Xocova is administered once daily for five days, unlike rival treatments from Pfizer ( PFE ) and Merck ( MRK )/ Ridgeback Biotherapeutics, which require twice daily dosing for five days.
• In April, London-based data analytics firm Airfinity projected Shionogi ( OTCPK:SGIOF ) to add $2.5 billion in sales in 2022 from its oral COVID-19 therapy.

For further details see: